Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Spunky Beaver who wrote (2706)	9/14/1998 9:23:00 AM
From: B Tate	Respond to of 4634

Spunky and Bill Sounds like Barb's indicator is warming up! ;-) Got to go check what else he is in! bt VGINF Didn't do any DD but company is involved in gene sequencing etc.

To: Spunky Beaver who wrote (2706)	9/14/1998 6:15:00 PM
From: mesaone	Read Replies (2) \| Respond to of 4634

I do not work in the medical community, so I asked one of my long friends on the yahoo message board to respond. He works in the medical profession. I did not want to give you just my impressions from what I have read, so I went to an expert. Mesaone, As you requested: I have taken the time to speak with several Cardiac Surgeons and Anesthesiologists about the volume expansion product, Hextend. The Beav may simply be talking to a doc who knows relatively very little about this product. When I first approached physicians they knew very little of the product Hextend. They have knowledge of hetastarch and things of the like. This is not surprising because there has been no marketing to date. Physicians hear about this type of thing through Journal Articles, hearsay, the Clinical Pharmacist in the hospital where they work, the RN's they work with, etc. Most physicians are very accustomed to using products that have served them reasonably well over time. Many do not entertain change unless there is suitable raeson to do so. In recent years, for obvious reasons, physicians are becoming more aware of reimbursement issues both for themselves and the hospitals where they practice. Communication has gradually improved between the somewhat natural enemies; the hospital administration and the physicians. One needs to consider the fact that most physicians are very busy trying to maintain their pre-nineties revenue stream and are not looking at these boards. In my opinion we need the product, the Journal Reviews, and some creative yet honest marketing. The docs inherently want to do the best for their patients but most do not want to plow new ground. Smaller groups and hospitals will likely take a "wait and see" approach to this product when it does come out. If it does what we all sincerely believe it will, then watch the hospitals and the docs come to the feeder. Abbott comes to my institution often yet they do not attempt to market the product. They can't and shouldn't until all FDA requirements are met. Smart on their part. You can bet they have their marketing ploy ready to go when all the ducks are in line. Abbott, Baxter, McGaw, and all the others are very very competitive. You watch, they will go for the big purchasing groups like Premiere when they get the green light. Longs do not be dismayed by the "beav", he/she may have actually run into some physician who does not know much about it. This is not bad and should not come as a surprise. We need the product on the market.

To: Spunky Beaver who wrote (2706)	9/14/1998 7:56:00 PM
From: mesaone	Read Replies (1) \| Respond to of 4634

beaver, since this was in response to your reply to me.... i thought you might want to read it. If you would like some accurate information about BioTime, please visit my web site: I a m a long time biotime shareholder who believes in providing accurate information about this company, unlike assensio's lies this past year. inch.com This is a first class company, with great products which will help the world and make the long investors rich.Given that there are almost 2 million shares still shorted, with a clock that is winding down to FDA approval soon... and a relatively small float..and the longs have been very enthusiastic about moving shares into non marginable accounts...you might want to reconsider your opinion about this company. Do you own DD and really get to know BioTime .This is a great price to be buying in at.. but please, make sure you buy in on non-marginable accounts, that i what we long investors have been doing all year. There is very little stock for the shorts to get their hands on now..and when they do go to cover... it will be at a long price. Beaver = a Short. That post about the person who HAS NO POSITION is BS. They list another short candidate of Assensio's as a comparison and got it wrong. The CCSI stock is not near 52 week low. See. There is one bold lie. This must be a Asencio follower of some kind. Be that as it may, they are so far off base they have no clue. Well, I will be damned if I will provide any info I know of BUT the folks who know of Hextend are some of the smartest minds out there, way over my head, but what they tell me and I have talked to more of them than any person here, is that this stuff is good it works, and ........any more I will tip my hat. Cannot wait for the shorts to be buried. Please get those shares in non margin accounts. Take Delivery . Help bury a short. !!!!!!!!